SCHEMBL161194

SCHEMBL161194

C[C@@H](O)[C@](C)(N)C(=O)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164800 1.00
SCHEMBL19862759 1.00
SCHEMBL21641518 1.00
SCHEMBL6848938 1.00
SCHEMBL574756 1.00
SCHEMBL9271747 1.00
SCHEMBL594190 1.00
Hydrochloric Acid SCHEMBL31757671 0.97 CYP1A2 (0.39)
Hydrochloric Acid SCHEMBL31757860 0.97 CYP1A2 (0.39)
SCHEMBL723877 0.80 CYP2D6 (0.41)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2145 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116921-A1 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES PROTAGONIST THERAPEUTICS INC (US) 2026-04-30 US claimed
EP-4727655-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP claimed
EP-4727653-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP claimed
EP-4727654-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF Mariana Oncology Inc. (US) 2026-04-22 EP claimed
EP-4658374-A1 METHODS FOR PREPARING CRYSTALLINE PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR Janssen Pharmaceutica NV (BE) 2025-12-10 EP claimed
EP-4613761-A9 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES Janssen Biotech, Inc. (US) 2025-10-22 EP claimed
EP-4622991-A2 SYNTHESIS OF A CYCLIC PEPTIDE Janssen Pharmaceutica NV (BE) 2025-10-01 EP claimed
EP-4613761-A2 PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES Janssen Biotech, Inc. (US) 2025-09-10 EP claimed
US-20250049970-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-02-13 US claimed
US-20250034210-A1 DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF MARIANA ONCOLOGY INC (US) 2025-01-30 US claimed
US-20120040915-A1 PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2012-02-16 US claimed
EP-1882737-B1 PROCESS FOR PRODUCTION OF L-SERINE DERIVATIVE AND ENZYME USED IN THE PROCESS AJINOMOTO KK (JP) 2011-09-14 EP claimed
WO-2011048614-A2 SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP-1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST CADILA HEALTHCARE LIMITED (IN) 2011-04-28 WO claimed
US-7851187-B2 Method of producing L-serine derivative and enzyme used therefore AJINOMOTO CO., INC. (JP) 2010-12-14 US claimed
WO-2010088527-A2 PEPTIDES AND NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) 2010-08-05 WO claimed
US-20090215895-A1 Therapeutic and carrier molecules PEPLIN BIOLIPIDS PTY LTD (AU) 2009-08-27 US claimed
US-20090170171-A1 Method of Producing L-Serine Derivative and Enzyme Used Therefore AJINOMOTO CO., INC. (JP) 2009-07-02 US claimed
EP-1882737-A1 PROCESS FOR PRODUCTION OF L-SERINE DERIVATIVE AND ENZYME USED IN THE PROCESS Ajinomoto Co., Inc. (JP) 2008-01-30 EP claimed
US-7256172-B1 Method of treatment and agents useful for same THE UNIVERSITY OF MELBOURNE (AU) 2007-08-14 US claimed
US-7070969-B1 Plasmin inhibitors from the australian brown snake Pseudonaja textilis textilis THE UNIVERSITY OF QUEENSLAND (AU) 2006-07-04 US claimed